02 · Clinical Findings
Incretin Drug May Improve Menstrual Regularity
In a prospective cohort of 1,945 participants, combined GLP-1/GIP drug users had a 2.5-day reduction in cycle length.

A combined GLP-1/GIP drug was linked to more regular menstrual cycles in a prospective cohort analysis.
Among 1,945 participants, users of the combination drug saw cycle length drop by 2.5 days, versus 0.4 days with GLP-1 drugs and 0.8 days among never-users.
Cycle variability was also lower, especially among participants with PMOS, formerly called PCOS. The findings show an association; further research is needed.
Read the full story at MedPage Today ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit

At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes

Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years

Continue reading · Clinical FindingsPeptide News / Clinical FindingsTriple-Target Incretin Drug Kills Knee Osteoarthritis Pain in ObesityMedPage Today · Nov 8, 2026 · scroll to read